Evidence map›Paper›PMID 36131737›Full record

ArticleNanoscale advances2021

Distribution in the brain and possible neuroprotective effects of intranasally delivered multi-walled carbon nanotubes.

Marzia Soligo, Fausto Maria Felsani, Tatiana Da Ros, Susanna Bosi, Elena Pellizzoni, Stefano Bruni, Jacopo Isopi, Massimo Marcaccio, Luigi Manni, Silvana Fiorito

Open access · goldAbstract read
In one paragraph

Article in Nanoscale advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Carbon nanotubes as neuroprotective agents.Exploration of neuroprotective therapy · 2024
    Article
  8. Review
  9. Review
  10. Nasal delivery of neurotherapeuticsFrontiers in pharmacology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Marzia SoligoInstitute of Translational Pharmacology, CNR Via Fosso del Cavaliere 100 00133 Rome Italy silvana.fiorito@ift.cnr.it.ORCID https://orcid.org/0000-0002-1420-0914
Fausto Maria FelsaniInstitute of Translational Pharmacology, CNR Via Fosso del Cavaliere 100 00133 Rome Italy silvana.fiorito@ift.cnr.it.
Tatiana Da RosINSTM - Trieste Unit, Department of Chemical and Pharmaceutical Sciences, University of Trieste Via Licio Giorgieri 1 34127 Trieste Italy.ORCID https://orcid.org/0000-0003-1932-1560
Susanna BosiINSTM - Trieste Unit, Department of Chemical and Pharmaceutical Sciences, University of Trieste Via Licio Giorgieri 1 34127 Trieste Italy.
Elena PellizzoniINSTM - Trieste Unit, Department of Chemical and Pharmaceutical Sciences, University of Trieste Via Licio Giorgieri 1 34127 Trieste Italy.
Stefano BruniFormer Medical Director Sanofi - Genzyme, Italy, currently Orchard Therapeutics 108 Cannon Street London UK.
Jacopo IsopiDepartment of Chemistry "G. Ciamician", University of Bologna Via Selmi, 2 40126 Bologna Italy.
Massimo MarcaccioDepartment of Chemistry "G. Ciamician", University of Bologna Via Selmi, 2 40126 Bologna Italy.ORCID https://orcid.org/0000-0001-9032-0742
Luigi ManniInstitute of Translational Pharmacology, CNR Via Fosso del Cavaliere 100 00133 Rome Italy silvana.fiorito@ift.cnr.it.
Silvana FioritoInstitute of Translational Pharmacology, CNR Via Fosso del Cavaliere 100 00133 Rome Italy silvana.fiorito@ift.cnr.it.ORCID https://orcid.org/0000-0001-9006-5702
Istituto di Farmacologia Traslazionale · ITUniversity of Trieste · ITUniversity of Bologna · ITForma Therapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbon nanotubes (CNTs) are currently under active investigation for their use in several biomedical applications, especially in neurological diseases and nervous system injury due to their electrochemical properties. Nowadays, no CNT-based therapeutic products for internal use appear to be close to the market, due to the still limited knowledge on their fate after delivery to living organisms and, in particular, on their toxicological profile. The purpose of the present work was to address the distribution in the brain parenchyma of two intranasally delivered MWCNTs (MWCNTs 1 and a-MWCNTs 2), different from each other, the first being non electroconductive while the second results in being electroconductive. After intranasal delivery, the presence of CNTs was investigated in several brain areas, discriminating the specific cell types involved in the CNT uptake. We also aimed to verify the neuroprotective potential of the two types of CNTs, delivering them in rats affected by early diabetic encephalopathy and analysing the modulation of nerve growth factor metabolism and the effects of CNTs on the neuronal and glial phenotypes. Our findings showed that both CNT types, when intranasally delivered, reached numerous brain areas and, in particular, the limbic area that plays a crucial role in the development and progression of major neurodegenerative diseases. Furthermore, we demonstrated that electroconductive MWCNTs were able to exert neuroprotective effects through the modulation of a key neurotrophic factor and probably the improvement of neurodegeneration-related gliosis.

Identifiers

PMID36131737
PMCPMC9418508
OpenAlexW3099851492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.